Endpoints NewsJuno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center …Business Wire (press release)SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company… Continue reading
Interesting EngineeringHow CRISPR Genome Editing Works and How It Could Make Us SuperhumansInteresting EngineeringPop culture has used DNA mutation to explain super-powers and animal mutations for decades — legendary comic book superhero Spider-man go… Continue reading
|
How I use biology as a tool for building
Baltimore Business Journal In 2010, I had some students who wanted to participate in an international competition in synthetic biology, called iGem. They asked if I’d be the faculty advisor and I said ‘Okay,’ but they had a hard time getting enough people for a team together. I … |
|
Stem Cell Treatment Targeting Spinal Cord Won’t Slow ALS, Researchers Say
ALS News Today Using stem cell treatments to protect motor neurons is not enough to prevent the loss of nerve-muscle connections and disease progression in a mouse model of amyotrophic lateral sclerosis (ALS), researchers from Italy found. The study, published in the … |
Endpoints News |
Looking for the next big breakthrough in CAR–T, Mike Gilman debuts Obsidian with $49.5M round
Endpoints News Building off some research work he’d done in the lab for years, the crew has been working with what he calls destabilizing domains, mutants which can be encoded in a “synthetic biologic cassette,” packaged in a vector and dispatched to tinker with an … Obsidian launches with $49.5 million to fine tune cellular and gene therapiesChemical & Engineering News Biogen vet launches cancer drug startup with $50M from GV, othersBoston Business Journal Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy …Business Wire (press release) |